Heart failure is a syndrome that results from the inability of the cardiac pump to function properly to ensure the metabolic demand of the body. Its affects more than 60 million of patients worldwide and is the only cardiac disease that continues to grow, despite standard of care, accross various HF subpopulations.
Pulmonary hypertension – group 2
Pulmonary hypertension (PH) Group 2, or PH due to left heart disease (PH-LHD), is caused by elevated left-sided cardiac filling pressures, most commonly from heart failure with preserved or reduced ejection fraction (HFpEF/HFrEF), which are transmitted backward into the pulmonary circulation and lead to adverse pulmonary vascular remodeling. PH Group 2 represents a major unmet medical need, given its high prevalence and its association with substantial morbidity, frequent hospitalizations, and increased mortality. Yet there are no therapies specifically approved to treat the pulmonary vascular component of PH Group 2. Management largely relies on treating the underlying left heart disease, while pulmonary arterial hypertension–targeted therapies, such as endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin analogs, have failed to demonstrate consistent benefit and may be harmful in some patients. Therefore, novel therapies are urgently needed for the treatment of PH Group 2 , a disease that is estimated to affect more than 30 million people worldwide.